Trial reportEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2015
GLYCATED ALBUMIN AT 4 WEEKS CORRELATES WITH A1C LEVELS AT 12 WEEKS AND REFLECTS SHORT-TERM GLUCOSE FLUCTUATIONS.
Trial report in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- Biodegradable microneedles for transdermal sitagliptin delivery: in vivo insights into enhanced diabetes management.Drug delivery and translational research · 2026Article
- Glycated albumin may have a complementary role to glycated hemoglobin in glucose monitoring in childhood acute leukemia.Annals of pediatric endocrinology & metabolism · 2024Article
- Usefulness of glycated albumin level as a glycemic index complementing glycosylated hemoglobin in diabetic children and adolescents.Annals of pediatric endocrinology & metabolism · 2023Article
- Glycated Albumin Correlates With Time-in-Range Better Than HbA1c or Fructosamine.The Journal of clinical endocrinology and metabolism · 2023Article
- Analytical performances of a glycated albumin assay that is traceable to standard reference materials and reference range determination.Journal of clinical laboratory analysis · 2022Article
- Glycated albumin as a biomarker for diagnosis of diabetes mellitus: A systematic review and meta-analysis.World journal of clinical cases · 2021Article
- Improved individual and population-level HbA1c estimation using CGM data and patient characteristics.Journal of diabetes and its complications · 2021Article
- Comparison of Premixed Human Insulin 30/70 to Biphasic Aspart 30 in Well-Controlled Patients with Type 2 Diabetes Using Continuous Glucose Monitoring.Journal of clinical medicine · 2021Article
- Review of methods for detecting glycemic disorders.Diabetes research and clinical practice · 2020Review
- Results of a Study Comparing Glycated Albumin to Other Glycemic Indices.The Journal of clinical endocrinology and metabolism · 2020Article
- Glycated albumin is correlated with glycated hemoglobin in type 2 diabetes.Medicine and pharmacy reports · 2019Article
- Incretin-based therapies for patients with type 1 diabetes: a meta-analysis.Endocrine connections · 2019Article
- Hemoglobin ADiabetes care · 2018Article
- Preoperative Diabetes Optimization Program.Clinical diabetes : a publication of the American Diabetes Association · 2018Article
- Alternate glycemic markers reflect glycemic variability in continuous glucose monitoring in youth with prediabetes and type 2 diabetes.Pediatric diabetes · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 2 countries.
Funding
Abstract
objectiveEvaluate the performance of glycated albumin (GA) monitoring by comparing it to other measures of glycemic control during intensification of antidiabetic therapy.
methodsThis 12-week, prospective, multicenter study compared the diagnostic clinical performance of GA to glycated hemoglobin A1C (A1C), fructosamine corrected for albumin (FRA), fasting plasma glucose (FPG), and mean blood glucose (MBG) estimated from self-monitoring of blood glucose (SMBG) and continuous glucose monitoring (CGM) in 30 patients with suboptimally controlled type 1 or 2 diabetes.
resultsMean A1C decreased from 9.5% to 8.1%. Mean SMBG correlated closely with CGM (Pearson r = 0.783 for daily estimates and r = 0.746 for weekly estimates, P<.0001). Both GA and FRA levels significantly correlated with changes from baseline in A1C and mean weekly SMBG (P<.001). The lowest observed median GA occurred at 4 weeks, followed by a small increase and then a slight reduction, mirroring changes in overall mean SMBG values. The median A1C fell throughout the treatment period, failing to reflect short-term changes in SMBG. A ≥1% reduction in GA at 4 weeks was significantly associated with a ≥0.5% change in A1C at 12 weeks (odds ratio [OR] = 19.0, 95% confidence interval [CI]: 1.4, 944, P = .018).
conclusionIn patients receiving glucose-lowering therapy, changes in GA at 4 weeks were concordant with changes in A1C at 12 weeks, and both GA and FRA more accurately reflected short-term blood glucose fluctuations than A1C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.